<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136279">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050880</url>
  </required_header>
  <id_info>
    <org_study_id>RS-3000 series Protocol 1</org_study_id>
    <nct_id>NCT02050880</nct_id>
  </id_info>
  <brief_title>OCT Agreement and Crossed Precision Study</brief_title>
  <official_title>Crossed Precision Design Study of the Nidek Optical Coherence Tomography RS-3000, RS-3000 Lite and RS-3000 Advance for the Measurements of Retinal and RNFL Thickness, Optic Disc Analysis, and Pachymetry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nidek Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nidek Co. LTD.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to asses the agreement of the RS-3000 Lite and RS-3000 Advance
      to the RS-3000, assess the crossed precision of each study device and to assess the
      transference of a reference database from the RS-3000 to the RS-3000 Lite and to the RS-3000
      Advance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Retinal thickness</measure>
    <time_frame>Approximately four hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame is the maximum duration of hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optic Disc Analysis</measure>
    <time_frame>Approximately four hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame is the maximum duration of hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Thickness</measure>
    <time_frame>Approximately four hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame is the maximum duration of hospital stay</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Glaucoma</condition>
  <condition>Retinal Disease</condition>
  <condition>Corneal Disease</condition>
  <arm_group>
    <arm_group_label>Normal eyes</arm_group_label>
    <description>Eyes without pathology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Eyes with Glaucoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinal</arm_group_label>
    <description>Eyes with Retinal Disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corneal</arm_group_label>
    <description>Eyes with corneal disease including a kerato-refractive group.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Clinic subjects, general population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: NORMAL EYES

          -  Subjects who do not have pathology in both eyes

        Inclusion Criteria: GLAUCOMA

          -  Subjects who have a glaucoma diagnosis

        Inclusion Criteria: RETINAL

          -  Subjects who have a retinal diagnosis including but not limited to:

               1. Diabetic macular edema

               2. Dry age related macular degeneration

               3. Wet age related macular degeneration

               4. Cystoid macular edema

               5. Epiretinal membrane

               6. Macular hole

        Inclusion Criteria: CORNEAL

          -  Subjects who has one of these diagnosis:

               1. Post status LASIK surgery

               2. Keratoconus

               3. Other corneal dystrophies or degenerations.

        Exclusion Criteria: ALL EYES

          -  Subjects who have any of the following conditions

               1. Diabetes mellitus (DM) and/or diabetic retinopathy

               2. Uncontrolled Hypertension (HT)

               3. Cerebral infarction, cerebral hemorrhage, cranial nerve neoplasm and other
                  central nervous system diseases affecting vision

               4. Cardiac, hepatic, renal and hematologic diseases

               5. A current condition requiring systemic administration of steroid

               6. A history of, or currently receiving, anticancer therapy

               7. Epileptic seizures which are optically induced

               8. Dementia

          -  Subjects who have other life threatening and debilitating systemic diseases

        Note:  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>WCCT Global Opthalmology Research Center</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnny Leng</last_name>
      <phone>312-925-0906</phone>
      <email>Johnny.Leng@wcct.com</email>
    </contact>
    <investigator>
      <last_name>Michael Sheety, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Normal Eyes</keyword>
  <keyword>Eye; Disorder with Glaucoma</keyword>
  <keyword>Eye; Disorder with Retinal Disease</keyword>
  <keyword>Eye; Disorder Corneal Disease incl kerato-refractive group</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
